The cannabis beverage category has spent the last two years proving it is not a novelty. Grand View Research projects the global cannabis beverages market to reach $3.86 billion by 2030 at a 19.2% CAGR – with North America accounting for 72.7% of global revenue and THC-based products representing 64.9% of the component mix.
The category is now operating inside serious retail footprints – Sprouts, Total Wine, grocery chains, and liquor stores in states that have built hemp-friendly frameworks.
Whatever happens with the November 12, 2026 effective date of the FY2026 Agriculture Appropriations Act’s revised hemp definition, the category has already demonstrated what consumers want: a low-dose, alcohol-alternative format that fits into an evening without the hangover.
The formulation question facing operators right now is whether their product actually delivers that experience. A surprising number do not – and the reason almost always traces back to one decision: how the cannabinoids get into the can.
Why Oil Infusion Keeps Failing the Format
Cannabinoids are hydrophobic. Drop THC distillate into water and it will not dissolve; it will bead, float, and eventually separate. The most common workaround in early hemp beverages was conventional oil infusion with a standard food-grade emulsifier.
In conventional hemp beverages, emulsifiers are paired with a surfactant, which coats and stabilizes the oil droplets in the water phase.
The conventional approach works well enough to produce a drinkable product on a short timeline, which is why so many brands started there. The problem is what happens after the consumer opens the can.
The Pharmacokinetic Problem
Conventionally oil-infused cannabinoids behave like edibles. They pass through the digestive tract, hit first-pass metabolism in the liver, and get converted into 11-hydroxy-THC before meaningful amounts reach circulation.
Onset stretches to 45 minutes to two hours. Bioavailability for traditional oral cannabinoids sits in the 4-12% range depending on the study, and the variance between individual consumers is substantial.
The same 5mg dose can feel negligible to one drinker and overwhelming to another – not because of tolerance, but because of how much of the cannabinoid actually reached the bloodstream and on what timeline.
The Category Problem
For a beverage sold as a social drink, this is a structural problem. Alcohol sets the expectation:
- One drink, effects within fifteen to twenty minutes
- Predictable arc, titrate from there
- Reliable enough to pace against food, conversation, and the rest of the evening
A hemp beverage that takes an hour to land and varies significantly between consumers is not competing with alcohol. It is competing with gummies, and losing on convenience.
What Nano-Emulsification Changes
Nano-emulsification breaks cannabinoid oil into droplets in the 20-200 nanometer range, stabilized by a carefully selected surfactant system. The process typically uses high-pressure homogenization or ultrasonication to drive the droplet size down.
The formulation work – choosing the right combination of surfactants, co-surfactants, and sometimes carrier oils – is what determines whether the emulsion stays stable in a carbonated, acidified, shelf-stable beverage for twelve to eighteen months.
Two things change at nano scale that matter for the finished product.
Water Compatibility and Shelf Stability
Below roughly 200nm, the emulsion is transparent or nearly so, does not cream or sediment, and can survive the shear and thermal stress of beverage processing without breaking. That solves the shelf-stability and mouthfeel problem – no oil slick on top of the can, no gritty texture, no separation.
Absorption and Consistency
Nano-sized droplets present vastly more surface area per unit of cannabinoid, and a meaningful fraction gets absorbed sublingually and through the gastric mucosa before ever reaching the liver.
A 2023 Karger study on UltraShear nanoemulsion CBD calculated oral bioavailability at 18.6% at six hours and 25.4% at 24 hours, roughly 3-4x higher than conventional oil-based formulations.
A more recent crossover study in the Journal of Cannabis Research found a self-nanoemulsifying delivery system produced a 2.9-fold increase in relative bioavailability for THC versus standard oil-based drops, with faster Tmax values across all measured cannabinoids.
Onset typically lands in the 10-20 minute range. Peak plasma concentration arrives much faster and – importantly – with tighter variance between individuals.
Nano-Emulsified vs. Conventional Oil Infusion
| Parameter | Conventional Oil Infusion | Nano-Emulsification |
| Droplet size | >1,000 nm (often much larger) | 20-200 nm |
| Water compatibility | Poor; requires heavy emulsifier loading | Effectively water-soluble |
| Onset time | 45-120 minutes | 10-20 minutes |
| Oral bioavailability | ~4-12% | ~15-25% |
| Consumer variance | High | Noticeably tighter |
| Shelf stability | Prone to creaming and separation | Stable for 12-18 months with proper formulation |
The bioavailability number matters, but the bigger formulation win is consistency. When the dose lands reliably at roughly the same time for roughly the same percentage of drinkers, the product behaves like a beverage instead of like an edible lottery ticket.
What This Means for What a Brand Can Credibly Claim
There is a gap right now between what hemp beverage marketing promises and what conventionally formulated products deliver. Claims like “fast-acting,” “predictable onset,” and “alcohol alternative” get used across the category regardless of whether the underlying formulation actually supports them.
Consumers notice. The first-time drinker who tries a conventionally infused 10mg THC seltzer at a summer barbecue, feels nothing for ninety minutes, opens a second, and then gets blindsided two hours in is not coming back to the category – and in trade terms, they are telling their friends not to either.
Three Claims a Nano-Formulated Brand Can Actually Back
When nano-formulated beverages are built properly, a few claims can be supported with confidence. These are the ones that matter most to real consumers and repeat buyers.
- Onset Within a Defined Window: Typically 10 to 20 minutes, consistent enough that a consumer can pace a second drink against the first without guessing. This is one of the most important drivers of repeat purchase in a social setting. If consumers can learn their dose, they are far more likely to reorder.
- Dosing Accuracy That Holds From Can to Can and Drinker to Drinker: This is partly about the emulsion’s homogeneity, meaning no hot spots or settling, and partly about narrower bioavailability variance at nano scale. A 10mg can that reliably feels like 10mg is a product people trust. A 10mg can that feels like 4mg one night and 14mg the next is a liability.
- An Experience That Parallels Alcohol’s Arc: Close enough that the consumer can substitute it for a drink without reorganizing their evening. That is a major reason the category is growing. It requires onset and offset that track more like a cocktail than a brownie.
Pharmaceutical-adjacent formulation does not get you a pharmaceutical claim, and operators should be careful about that line. But it does let you describe the experience honestly – and in a category where most products still under-deliver on their marketing, honest and accurate is a competitive position.
A Reference Point From the Brand Side
Mellow Fellow is useful to look at here because the formulation decision came before the brand decision. The company was built by a PhD chemist and a pharmacist around a proprietary nano-emulsion process.
The product line – 10mg Delta-9 THC and 10mg CBD seltzers – was designed against the faster-onset, tighter-variance profile that technology enables, rather than being retrofit onto it.
That is a different starting point from most of the category, where the brand identity comes first and the formulation gets sourced to a co-packer later.
It is not the only approach that works, and there are capable nano-emulsion contract formulators serving the category now. But the operators treating formulation as the product rather than as a procurement line item are the ones producing drinks that behave the way the category’s marketing claims they do.
Where This Leaves Operators Making Decisions Now
The regulatory picture for intoxicating hemp products is genuinely uncertain going into the back half of 2026, and no one should pretend otherwise. But the formulation question is separate from the regulatory question, and it applies whether a brand is operating in the hemp lane, the state-licensed cannabis lane, or hedging across both.
Two things are true at once:
- The category is consolidating around brands that can execute at beverage-industry standards on shelf stability, flavor, and consumer experience
- The consumer experience in this format is almost entirely determined by how the cannabinoid is delivered, not by what the cannabinoid is
Operators still running on conventional oil infusion because it was the cheapest path to a launch SKU are making a decision that will become more visible as the category matures. Consumers comparing a nano-emulsified 5mg seltzer that lands in fifteen minutes against an oil-infused 10mg seltzer that lands in ninety are going to pick the first one, and they are going to keep picking it.
Repeat purchase in this category runs on whether the drink does what the can says it does. Nano-emulsification is not the only way to get there, but it is currently the most reliable one – and the operators treating it as a core formulation decision rather than a nice-to-have upgrade are the ones positioned for where this category is heading.
The brands that survive whatever the next eighteen months bring – federal reform, state-by-state patchwork, or something in between – will be the ones whose products the consumer can learn. Formulation is where that starts.
